Research | Sample | Age/years | Sex ratio (males/females) | Course of T2DM/years | Interventions | Duration | Outcomes | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
T/C | T | C | T | C | T | C | T | C | |||
Zha 2018 [16] | 30/30 | – | – | – | – | – | – | LIR(0.6 to 1.8 mg qd ih) plus Huang kui capsule | Huangkui Capsules 2.5 g tid po | 2 months | ACDF |
Cao 2020 [17] | 30/30 | 55.21 ± 6.32 | 56.12 ± 6.92 | 17/13 | 15/15 | 4.08 ± 1.74 | 4.19 ± 1.52 | LIR(0.6 to 1.2 mg qd po) plus nephritis rehabilitation tablets | nephritis rehabilitation tablets 0.48 g/tablet, 5tablets/time, tid | 12 weeks | ABCGHIJK |
Dong 2018 [18] | 43/43 | 53.7 ± 6.2 | 54.6 ± 8.7 | 20/23 | 23/20 | – | – | LIR(0.6 to 1.8 mg qd ih) + INS | INS | 6 months | ABCDEFGH |
Chen 2016 [19] | 30/31 | – | – | – | – | – | – | LIR(0.6 to 1.8 mg qd ih) + RT | RT | 24 weeks | ACDEH |
Hu Yanyun 2018 [20] | 55/55 | 59.64 ± 6.51 | 59.66 ± 6.54 | 35/20 | 37/18 | 6.28 ± 1.23 | 6.39 ± 1.14 | LIR(0.6 to 1.2 mg qd ih)plus RT | RT | 8 weeks | ABCHK |
Ren Lijuan 2019 [21] | 15/15 | 44.8 ± 2.7 | 51.3 ± 2.9 | 7/8 | 9/6 | – | – | LIR (0.6 to 1.8 mg tid po) plus huangkui capsules | Huangkui Capsules 2.5 g tid | 6 months | ABCF |
Ren Wei 2015 [22] | 24/24 | – | – | – | – | – | – | LIR(0.6 to 1.8 mg qd ih) + RT | RT | 6 months | ACDFH |
Shi 2019 [23] | 30/30 | 57.32 ± 3.69 | 57.63 ± 3.12 | 17/13 | 18/12 | 7.13 ± 2.24 | 7.08 ± 1.71 | LIR (0.6 to 1.2 mg qd ih) plus Benazepril 10 mg qd | Benazepril 10 mg qd | 10 weeks | CHJKH |
Yang 2016 [24] | 100/100 | 66.8 ± 14.7 | 67.4 ± 13.5 | 45/55 | 48/52 | – | – | LIR (0.6 to 1.2 mg qd ih) plus Telmisartan 40 mg qd | Telmisartan 40 mg qd | 10 weeks | CHJK |
Zhao 2014 [25] | 19/26 | – | – | – | – | – | – | LIR (0.6 to 1.8 mg qd ih) plus Valsartan | Valsartan 80 mg qd | 6 months | CDI |
Zheng 2015 [26] | 110/110 | 58 ± 4.9 | 57 ± 5.1 | 67/43 | 65/45 | 6.9 ± 2.8 | 7.1 ± 2.4 | LIR (0.6 to 1.2 mg qd ih) plus INS | INS | 4 weeks | ADGH |
Hu Linlin 2018 [27] | 30/30 | 42.5 ± 11.6 | 41.3 ± 10.7 | 18/12 | 17/13 | – | – | LIR(0.6 to 1.8 mg tid po) plus huangkui capsules | Huangkui Capsules 2.5 g tid po | 6 months | ACDF |
Aiyitan 2017 [28] | 89/73 | 58.1 ± 8.1 | 57.8 ± 7.9 | 49/40 | 39/34 | – | – | LIR(0.6 to 1.8 mg qd ih) plus RT | RT | 8 weeks | ABF |
Shen 2017 [29] | 30/30 | – | – | 17/13 | 16/14 | – | – | LIR (0.6 to 1.2 mg qd ih) pluse Olmesartan 20 mg/d | Olmesartan 20 mg/d | 6 months | ACFHJK |
Liu Rui 2016 [30] | 59/75 | 57.5 ± 7.4 | 58.2 ± 7.9 | 33/26 | 43/32 | – | – | LIR (0.6 to 1.2 mg qd ih) plus RT | RT | 8 weeks | ABF |
Liu Chuyv 2015 [31] | 13/13 | – | – | – | – | – | – | LIR (0.6 to 1.2 mg qd ih) + Olmesartan | Olmesartan 20 mg qd + INS | 6 months | DFI |
Li 2017 [32] | 21/21 | 48.2 ± 9.0 | 49.1 ± 8.3 | 11/10 | 13/8 | 4.2 ± 1.1 | 7.38 ± 1.5 | LIR plus RT | RT + INS | 12 weeks | ABCDEGH |
Jian 2018 [33] | 58/58 | 56.51 ± 6.05 | 56.33 ± 8.63 | 32/26 | 29/29 | – | – | LIR (0.6 mg to 1.2 mg qd ih) plus Metformin | Metformin 1 g bid | 3 months | ABCDFHJK |